ABSTRACT
INTRODUCTION
Prostate cancer is the second leading cause of cancer mortality in American men with an estimated 164,690 new cases in 2018. When diagnosed locally and treated, patients can expect a 99% 5-year survival rate. Once cancer has metastasized or recurred, however, the 5-year survival rate drops to 29% driving ongoing research to identify and treat patients harboring aggressive tumors. 1 Currently available nomograms are unable to distinguish patients with indolent disease from those likely to experience metastasis. Thus, current studies focus on understanding the individual steps of metastasis in an attempt to develop new methods to identify patients with aggressive disease. The first steps of the metastatic process: epithelial-mesenchymal transition, local invasion, intravasation, and survival in the circulation, represent early targets for identifying patients with aggressive tumors.
2-4
Cancer cells completing these steps become circulating tumor cells.
Circulating tumor cells (CTCs) are released at a rate of 3.2x10 6 cells/g tissue daily,
however, <0.01% of these cells will initiate metastases.
3,5
It remains unknown how CTCs initiate metastases due to an inability to examine the journey of CTCs from the primary tumor to the metastatic niche. 6 A subset of CTCs postulated to drive metastasis are cancer stem cells (CSCs).
7,8
The CSC theory postulates that a subpopulation of tumor cells remaining after resection drive recurrence, while the CTCs surviving the circulation and arresting at metastatic sites driving tumor growth are metastatic CSC. 9 In either case, CSCs are capable of self-renewal and asymmetric division and may be able to recapitulate the initial tumor heterogeneity. Further, these CSCs are more resistant to most treatments.
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While multiple markers were proposed for prostate cancer CTCs, 17 most have yet to be validated in the circulation of patients.
Several markers for CTCs and CSCs have been postulated in the literature. 17 In a prior study, we identified CD117/c-kit positive CTCs in prostate cancer patients that were associated with cancer severity and biochemical recurrence. 18 CD117+ cell numbers were increased in the prostate tissue and circulation of patients with Gleason 8+ disease. Further, three months postoperatively, CD117 CTC numbers were equal or increased in patients with recurrent cancer; while CD117 levels had dropped 50% in patients for whom surgery was successful. Additional studies demonstrated that CD117 expression in prostate cancers was increased with Gleason score and was expressed by both stromal cells in the transitional zone and cancer cells in the peripheral zone. 19 CD117 is expressed on both normal stem cells and aggressive cancer cells. 20 CD117 expression is found on hematopoietic stem cells (HSCs) and stem cells in the murine prostate. 21, 22 A single CD117 positive cell which was also Lin-Sca-1+ CD133+ CD44+ regenerated an entire secreting prostate when mixed with urogenital mesenchymal cells and implanted in the renal capsule. 21 Thus, this CD117 expressing cell was considered a prostate stem cell in adult tissue. Further, CD117 is a member of the type III tyrosine kinase receptors which play a key role in cell signaling and are responsible for maintaining cell functions such as cell survival, metabolism, cell growth and progression, proliferation, apoptosis, cell migration, and cell differentiation. 20, [23] [24] [25] These effects of CD117 activation and signaling support its potential role in prostate cancer progression and CSC maintenance. How CD117 activation alters proliferation, stemness, and migration remains to be elucidated.
The present study aimed to determine the extent to which the CTC marker CD117 was involved in prostate cancer progression, CSC maintenance, and therapeutic resistance. The human prostate cancer cell line LNCaP-C4-2 was separated into CD117+ and negative populations and the differences between the two subpopulations examined. The effects of CD117 activation by SCF treatment or inhibition by tyrosine kinase inhibitor (TKI) treatment were also tested. Using live cell imaging and xenograft models, we determine that CD117 activation drives progression, stemness, migration, and TKI resistance.
METHODS

Cell Culture, Sorting, and Treatment
To examine how CD117 expression alters cell function, human prostate cancer cells For sphere formation assays, 1,000 sorted LNCaP-C4-2 cells were plated in ultra-low attachment plates and imaged over nine days. Sphere area was calculated over time. Separate groups were treated with inhibitors or starved overnight before SCF treatment.
Quantitative PCR Gene Expression
To examine gene expression, cells and spheres were lysed using the Qiagen RNeasy kit and cDNA synthesized using the Applied Biosystems High Capacity cDNA Reverse Transcription kit.
Primer sequences are listed in 
Tumor Microarray Analysis
To assess whether CD117 was activated in prostate cancers, we obtained tissue microarrays Slides were scanned on a Hamamatsu Photonics NanoZoomer by the Virtual Microscopy Core.
Staining was quantified using Indica Labs HALO software and grouped according to Gleason Score.
Tumor Cell Invasion
To test cell invasion, we utilized a matrigel-coated transwell invasion assay. Sorted
LNCaP-C4-2 cells (1 x 10 5 cells/well) were plated in serum-free media on matrigel coated inserts (Corning BioCoat). The bottom chamber was filled with either complete media or complete media containing 50 ng/mL SCF. After 48 hours, transwell inserts were washed and fixed in 10% formalin overnight. Transwell inserts were then incubated in 100% methanol for 30 minutes followed by staining with Hematoxylin for 30 minutes. Five fields per insert (two inserts per group) were photographed using a ZMZ1000 (Nikon) microscope and cells/field were counted using NIH Image J.
Statistical Analysis
To determine statistical significance, Student's t test or one-way analysis of variance with
Tukey post-test were used to analyze data with the GraphPad Prism 7 software (RRID: SCR_002798). Error bars represent the SEM of experiments. * p<0.05, ** p<0.01, and *** p<0.005. Experiments were repeated at least three times.
RESULTS
CD117 Expression Stimulates Prostate Cancer Aggressiveness
In a prior study, we demonstrated that the number of CD117+ cells circulating in prostate cancer patients was associated with cancer severity and biochemical recurrence. 18 Based on these findings, we asked how CD117 expression on these cells promoted prostate cancer progression. In an initial study, we showed that CD117+ LNCaP-C4-2 xenograft tumors were larger and more angiogenic than tumors containing the negative population. 18 To further determine how CD117 expression drives prostate cancer aggressiveness, we sorted LNCaP-C4-2 human prostate cancer cells into CD117+ and negative populations. Using live cell imagining, we examined differences between these two populations. In a proliferation assay, CD117+ cells proliferated more quickly than the negative cells. CD117+ cells reached confluency peak at hour 58 at which point CD1117+ cells were 2.9-fold more confluent than the negative population ( Figure 1A ). Thus, in monolayer culture, CD117 promotes proliferation.
Since CD117+ cells were found in the patient circulation; we examined cancer cell migration using a scratch assay. Confluent CD117+ and negative cells were scratched to generate a wound and cell movement into the wound was measured by live cell imaging. CD117+ cultures showed increased confluence within the wound and decreased wound width over time ( Figure 1B and C). Upon experimental termination, CD117+ cell wound closure was 2.7-fold higher while the wound width was 1.7-fold smaller compared to the negative population. Thus, CD117 expression increases cell migration in two dimensional culture.
Another marker of aggressive tumor cells is the ability to form spheres. 15 Figure 2B ). Interestingly, the ligand for CD117, SCF, expression was also increased with 3D growth of the CD117+ cells. (Figure 2B ). No significant difference was seen between negative culture conditions ( Figure 2B ). Taken together, these data demonstrate that CD117 expression drives prostate cancer progression and this effect is increased when cells are grown in 3D spheres.
CD117+ Cells Are Cancer Stem-like Cells
More invasive cancer cells that form prostaspheres have the potential to CSCs, 15 Gene expression of Oct4 and Sox2 were 2.5-and 15.5-fold higher in CD117+ cells compared with the negative population ( Figure 3A ). To further demonstrate pluripotency, self-renewal capacity is measured by clonogenic assays and serial in vivo tumor initiation or limiting dilution experiments designed to examine whether a population could regenerate an entire tumor and thus be considered a CSC. while the negative implants were unable to initiate secondary tumors ( Figure 3D ). Thus, CD117
positive cells represent a prostate CSC subpopulation.
SCF Activation of CD117 Increases Prostate Cancer Progression
Based on these data demonstrating that CD117 expression drives prostate cancer progression, we questioned how activation of CD117 might alter these effects. CD117 is activated by the binding to SCF, its sole ligand. SCF, found in a dimer, binds to CD117 inducing dimerization, phosphorylation, and downstream signaling leading to proliferation, cytoskeletal rearrangement, and migration. 36, 37 To examine how activation of the tyrosine kinase receptor CD117 may alter prostate cancer aggressiveness, we first examined phosphorylated (p-)CD117 levels in prostate cancer patients. The numbers of p-CD117+ cells per core increased with Gleason Score ( Figure 4A ). Tumors from patients with Gleason 8+ cancers contained 2.2-fold more p-CD117+ cells compared with Gleason 6 patient tumors. Thus, activated CD117 is increased in patients with cancer severity.
Next, we examined how CD117 activation by SCF alters prostate cancer cell aggressiveness. 
CD117 Inhibition by TKIs Prevents Prostate Cancer Progression
Since CD117 activation induced prostate cancer progression and migration, we next examined the effects of treatment with the tyrosine kinase inhibitors (TKIs): sunitinib, imatinib, and ISCK03. Sunitinib targets several pathways and receptors including PDGFR and VEGFR in addition to CD117. 20, [38] [39] [40] Imatinib targets CD117, in addition to BCR-Abl, RET, and PDGFR. 38, 41 ISCK03 is a cell-permeable CD117 specific inhibitor that blocks SCF-induced phosphorylation. [42] [43] [44] In proliferation studies, sunitinib had the greatest reduction of proliferation for CD117+ cells (85% at 70 hours), while ISCK03 treatment resulted in a 50% reduction in proliferation and imatinib treatment did not affect proliferation ( Figure 5A ). We next examined the effect of tyrosine kinase inhibitors on growth in 3D. In contrast to proliferation in monolayer, imatinib had the strongest effect inhibiting sphere growth 66%; while sunitinib induced 50% inhibition and ISCK03 had minimal effect at hour 136 ( Figure 5B ). Taken together, these data demonstrate that TKIs decrease CD117 induced proliferation and sphere formation but the effects of the individual TKIs are dependent on the culture conditions. Overall our data demonstrate that CD117 activation plays a key role in prostate cancer, progression, migration, and resistance to TKI.
DISCUSSION
In this study, we determined how the CTC marker CD117 expression and activation affected prostate cancer progression. CD117 expression on human prostate cancer LNCaP-C4-2 cells induced increased proliferation, migration, and sphere formation. CD117+ cells expressed stemness marker genes and generated tumors in serial tumor initation studies indicating that CD117-expressing cells represent a CSC. Beyond expression, CD117 activation was increased with cancer severity. SCF activation of CD117 stimulated further proliferation and invasion but had no additional effect on CSC genes. Conversely, CD117 inhibition by TKIs diminished cell proliferation and sphere formation. Our data suggest that CD117 activation drives prostate cancer progression, invasion, and TKI resistance through its induction of the CSC phenotype.
We demonstrate that CD117 expression induces prostate cancer progression and its activation increases with cancer severity. CD117 expression and overactivation is found in several cancers including gastrointestinal stromal tumors (GIST), acute myelogenous leukemia, and melanoma. 20, 23, [45] [46] [47] CD117 is best studied in GIST which carry activating mutations. In GIST, CD117 expression and activation is associated with worse prognosis and bone metastasis. [48] [49] [50] [51] However, activating mutations have only been found in GIST despite increased CD117 expression in prostate and ovarian cancers among others. 20, 47, 52 CD117 expression in many cancers is associated with shorter disease survival and metastasis and CD117 is increased with cancer progression in prostate cancer patients with the highest levels of CD117 staining seen in bone metastases. 20, [52] [53] [54] However, the opposite is true in myeloid/erythroid cancers, whose patients have improved or unchanged prognosis when CD117 is expressed. 55 This may be partially due to biological differences between hematologic malignancies and solid tumors in which some genes and miRNA have opposite functions. 56 Further, in solid tumors, cancer cells are often the result of dedifferentiation whereas in hematological malignancies cancer cells are often transformed
HSCs or from earlier lineage cells. Thus, the differences in CD117 function in these tumors may relate to the degree of "stemness".
Our data indicate that the CD117 subpopulation represents a prostate CSC. This finding is supported by data demonstrating that CD117 expressing cells in the normal prostate are also stemlike. CD117+ prostate stem cells were found in all murine prostate lobes and in both the luminal and basal compartments. Prostates generated from a single CD117+ cell contained neuroendocrine synaptophysin-positive cells and expressed probasin and Nkx3.1. 21 Additionally, CD117 is a well-known stem-cell marker for normal hematopoietic cells and its expression declines as cells lose their plasticity during differentiation. [57] [58] [59] Further, in other cancer types, including lung and ovarian cancers, CD117 expressing cells exhibited CSC characteristics including self-renewal. [60] [61] [62] In osteosarcomas, CD117 is expressed on CSC and confers resistance to chemotherapies. 63 In this study, CD117+ osteosarcoma cells formed spheres and successfully initiated tumors after serial transplantation similar to our findings with the prostate cancer cell line. Further, in accordance with previous studies for prostate cancer, CD117 expression was higher in metastatic osteosarcoma tumors. Thus, CD117 expression appears to correlate with an ability to metastasize to bone. Our prior study demonstrating CD117 expression on CTCs, in combination with this study demonstrating CD117+ cells are tumor-initiating cells, suggests that CD117 likely plays an important role in driving bone metastasis; although future studies are needed to examine a causal link.
CD117+ cell escape from the primary tumor could be caused by chemotaxis towards SCF as demonstrated by our in vitro data. SCF plays an important role in the homing to and maintenance of HSCs in the bone microenvironment. 53, 59, 64, 65 Bone marrow niche cells secreting SCF include perivascular cells, endothelial cells, pericytes, mesenchymal stem cells, megakaryocytes, and stromal cells. 66, 67 Additionally, osteoblasts produce SCF and control CD117 expressing HSC numbers near trabeculae. 68 Correspondingly, SCF deletion in endothelial cells or pericytes leads to HSC depletion in bone marrow. 66, 69, 70 Bone marrow SCF also plays an important role in cancer and metastasis. Bone marrow stromal cells and prostate cancer express membrane SCF and release soluble form. However bone marrow stromal cells express much higher levels of the soluble SCF. 53 These data indicated that SCF in the bone marrow might function as a chemoattractant stimulating prostate cancer bone metastasis as already demonstrated by Ewing's sarcoma metastasis to bone. 71 Interestingly, LNCaP-C4-2 prostate cancer cells contain a subpopulation of CD117+ cells, while the LNCaP parental subline does not. It is likely that the exposure of the LNCaP cells to bone marrow during the generation of the C4-2 subline induced CD117 expression. This was shown with the PC3 cells that once exposed to bone marrow cells started to express CD117. 53 In other cell types, SCF treatment can induce CD117 expression but can also induce internalization of the receptor. TKIs, such as imatinib, for the CD117 activation site. 74 Our data demonstrate that CD117+ prostate cancer CSCs do not have a strong response to TKI treatment and that their response is context dependent. The TKIs imatinib and sunitinib were developed for and have a higher specificity for other tyrosine kinases. The lack of CD117+ cell response may be one reason for the failures of these TKIs in clinical studies. 75 Further, for prostate cancer, TKIs were given to patients with castration-resistant metastatic disease, which may be too late for the treatments to show efficacy. However, cabozantinib treatment in castration-resistant prostate cancer patients demonstrated tumor reduction and smaller bone metastases, 76 which was not tested in this study, had a higher specificity for CD117 than either imatinib or sunitinib. 20 Further, SCF in the bone microenvironment alters the efficacy of treatments, especially TKIs which have off-target effects in bone. 77 TKIs induce osteonecrosis in the jaw even when combined with bisphosphonates. 78 One possible reason may be stimulation of osteoclast and osteoblast differentiation by SCF. Another confounding factor is that tumor microenvironment SCF induces imatinib resistance by competing for the binding site with a higher affinity for CD117. 74 Imatinib, in particular, works better on inactive CD117 and prevents activation, but doesn't bind to activated CD117. 79 Thus, the high levels of SCF in the bone microenvironment may prevent TKI treatment from working properly on CD117 expressing prostate cancer cells, the numbers of which increase after exposure to the bone marrow. 53 The failures of prior TKI research may be due to the testing of inhibitors in patients who had already developed bone metastases. 75 This may be too late to alter progression and TKIs could be more effective earlier in the metastatic process. Further, failures may be due to the low specificity of current TKIs for CD117. 20 In combination with our prior data showing a CD117+ CTC population in advanced prostate cancer patients, the data from this study demonstrate that CD117 expression in primary tumors and on CTCs may identify advanced cancer patients likely to have more aggressive tumors leading to recurrence and metastasis. Further research is required to verify that CD117 expressing cells represent CSCs in patients and that these cells initiate bone metastases, which would require the development of new bone metastases models. 80 In summary, we demonstrate that the CD117 subpopulation of LNCaP-C4-2 prostate cancer cells represent CSCs driving progression, migration, and TKI resistance. 
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